{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-117913","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2026-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.566938+00:00","generated_at":"2026-05-15T09:29:20.796145+00:00","sec_items":["1.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"REGENXBIO settles GSK sublicense fee dispute for $10M","bullets":["Company will pay $10.0M to GSK within 3 business days for alleged underpayment of sublicense fees.","Settlement includes mutual releases of past claims and certain future claims under the 2009 license agreement.","Company retains existing allocation methodology for future sublicense fee payments to GSK.","Dispute covered sublicense fees and royalties on amounts received from sublicensees."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-117913","json":"https://secwatch.observer/filing/0001193125-26-117913.json","markdown":"https://secwatch.observer/filing/0001193125-26-117913.md","text":"https://secwatch.observer/filing/0001193125-26-117913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/rgnx-20260318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:29:20.796145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c12e231e4a45f79d0d62d320d32a74dcb40a4903","claim":"REGENXBIO Inc. entered into Settlement and Release Agreement with GlaxoSmithKline LLC valued at $10.0 million (effective 2026-03-18).","evidence_excerpt":"On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001437749-26-014906","ticker":"SGRP","company_name":"SPAR Group, Inc.","filed_at":"2026-05-05T23:59:59+00:00","headline":"SPAR Group settles arbitration with founder Robert Brown; extends CIC agreement to 2028","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-014906","json":"https://secwatch.observer/filing/0001437749-26-014906.json","markdown":"https://secwatch.observer/filing/0001437749-26-014906.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/0001437749-26-014906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/sgrp20260505_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm","comparable_excerpt":"On May 1, 2026, the Company entered into a Settlement Agreement and Release with Robert G. Brown and SPAR Business Services, Inc. allowing for a dismissal of the Arbitration action between the Company and Robert G. Brown.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/0001437749-26-014906-index.htm"}},{"accession":"0001193125-26-157030","ticker":"MCHX","company_name":"MARCHEX INC","filed_at":"2026-04-15T23:59:59+00:00","headline":"Marchex settles civil lawsuit for $2M, payments spread over 13 months","event_type":"litigation","sec_items":["1.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-157030","json":"https://secwatch.observer/filing/0001193125-26-157030.json","markdown":"https://secwatch.observer/filing/0001193125-26-157030.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/mchx-20260414.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm","comparable_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm"}},{"accession":"0001628280-26-024527","ticker":"CPT","company_name":"CAMDEN PROPERTY TRUST","filed_at":"2026-04-09T23:59:59+00:00","headline":"Camden Property Trust settles RealPage antitrust class action for $53M","event_type":"litigation","sec_items":["1.01","7.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-024527","json":"https://secwatch.observer/filing/0001628280-26-024527.json","markdown":"https://secwatch.observer/filing/0001628280-26-024527.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/906345/000162828026024527/0001628280-26-024527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906345/000162828026024527/cpt-20260407.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm","comparable_excerpt":"On April 7, 2026, Camden Property Trust, on behalf of itself and related entities (collectively, the “Company”) entered into a binding term sheet for a settlement with the named plaintiffs in the Class Action Litigation, individually and on behalf of the class members (together, the “Plaintiffs”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/906345/000162828026024527/0001628280-26-024527-index.htm"}},{"accession":"0001829126-26-003120","ticker":"SLND","company_name":"Southland Holdings, Inc.","filed_at":"2026-04-02T23:59:59+00:00","headline":"Southland subsidiary settles WA convention center lawsuit; sureties to pay additional $26.5M","event_type":"litigation","sec_items":["1.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-003120","json":"https://secwatch.observer/filing/0001829126-26-003120.json","markdown":"https://secwatch.observer/filing/0001829126-26-003120.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1883814/000182912626003120/0001829126-26-003120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1883814/000182912626003120/southland_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm","comparable_excerpt":"On March 27, 2026, American Bridge Company (“American Bridge”), a wholly owned subsidiary of Southland Holdings, Inc. (the “Company”), entered into a Settlement Agreement and Release of Claims (the “Settlement Agreement”) with Clark/Lewis, a Joint Venture (“Clark/Lewis”), certain sureties of American Bridge (the “Sureties”), the Washington State Convention Center (“WSCC”), and American Bridge’s litigation counsel.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1883814/000182912626003120/0001829126-26-003120-index.htm"}},{"accession":"0001437749-26-015945","ticker":"ICCC","company_name":"IMMUCELL CORP /DE/","filed_at":"2026-05-08T23:59:59+00:00","headline":"ImmuCell settles Norbrook dispute, to receive $2M payment","event_type":"litigation","sec_items":["1.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-015945","json":"https://secwatch.observer/filing/0001437749-26-015945.json","markdown":"https://secwatch.observer/filing/0001437749-26-015945.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/iccc20260508_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm","comparable_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm"}},{"accession":"0001628280-26-027280","ticker":"OPY","company_name":"OPPENHEIMER HOLDINGS INC","filed_at":"2026-04-27T23:59:59+00:00","headline":"Oppenheimer settles cash-sweep class action for $70M, to impact Q1 earnings","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-027280","json":"https://secwatch.observer/filing/0001628280-26-027280.json","markdown":"https://secwatch.observer/filing/0001628280-26-027280.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/0001628280-26-027280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/opy-20260424.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm","comparable_excerpt":"On April 24, 2026, Oppenheimer & Co., Inc. (“Oppenheimer”), the principal operating subsidiary of Oppenheimer Holdings Inc. (the “Company”), reached an agreement to settle the previously disclosed litigation styled Liberty Capital Group, Individually and on Behalf of All Others Similarly Situated v. Oppenheimer Holdings Inc., Oppenheimer & Co. Inc., and Oppenheimer Asset Management Inc. , No. 1:25-cv04822-JSR which was filed in the United States District Court for the Southern District of New York in June of 2025 (the “ District Court”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/0001628280-26-027280-index.htm"}},{"accession":"0001805651-26-000038","ticker":"MKTW","company_name":"MARKETWISE, INC.","filed_at":"2026-04-24T23:59:59+00:00","headline":"MarketWise settles arbitration with former CEO for $12.16M cash, redeems 520,867 units, terminates TRA rights","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation"],"urls":{"canonical":"https://secwatch.observer/filing/0001805651-26-000038","json":"https://secwatch.observer/filing/0001805651-26-000038.json","markdown":"https://secwatch.observer/filing/0001805651-26-000038.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/0001805651-26-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/mktw-20260421.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm","comparable_excerpt":"On April 21, 2026, Marketwise, Inc. (the “Company”) and its subsidiary, MarketWise, LLC (together with the Company, “MarketWise”), entered into a Settlement Agreement and Release (the “Settlement Agreement”) with Mark P. Arnold, the Company’s former Chief Executive Officer, and JAMA 2021, LLC (together with Mr. Arnold, the “Arnold Parties”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/0001805651-26-000038-index.htm"}},{"accession":"0001171843-26-002591","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-04-21T23:59:59+00:00","headline":"Allied Gaming settles litigation with Knighted for ~$5.94M paid over 3 months; CEO Li personally guarantees payment","event_type":"litigation","sec_items":["1.01","5.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002591","json":"https://secwatch.observer/filing/0001171843-26-002591.json","markdown":"https://secwatch.observer/filing/0001171843-26-002591.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/0001171843-26-002591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/f8k_042026.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526117913/0001193125-26-117913-index.htm","comparable_excerpt":"On April 10, 2026, Allied Gaming & Entertainment Inc. (the “Company”) and Yangyang Li, its Chief Executive Officer and Chairman, in his personal capacity (“Mr. Li”, and together with the Company, the “Allied Parties”) entered into a binding Term Sheet for Global Resolution (the “Term Sheet”) with Knighted Pastures, LLC (“Knighted”) and Roy Choi, in his personal capacity (“Mr. Choi”, and together with Knighted, the “Knighted Parties”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/0001171843-26-002591-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}